Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$1.20	$0.91	$0.23 ▼ $3.70	$127.76M	-0.09	4.61 million shs	2.74 million shs
EQ Equillium	$2.26	$2.07	$0.27 ▼ $2.70	$142.89M	1.67	261,593 shs	467,385 shs
KLRS Kalaris Therapeutics	$4.92	$5.93	$2.14 ▼ $11.88	$117.06M	0.15	92,250 shs	87,157 shs
MYNZ Mainz Biomed	$3.33 -6.5%	$0.92	$0.55 ▼ $4.43	$30.17M	0.31	371,589 shs	8.76 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	0.00%	+15.38%	+20.00%	+89.66%	+229.13%
EQ Equillium	0.00%	+22.83%	+4.63%	+17.71%	+456.65%
KLRS Kalaris Therapeutics	0.00%	+3.80%	-19.48%	-55.15%	+76.34%
MYNZ Mainz Biomed	0.00%	-3.76%	+556.03%	+444.12%	+58.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$1.20	$0.91	$0.23 ▼ $3.70	$127.76M	-0.09	4.61 million shs	2.74 million shs
EQ Equillium	$2.26	$2.07	$0.27 ▼ $2.70	$142.89M	1.67	261,593 shs	467,385 shs
KLRS Kalaris Therapeutics	$4.92	$5.93	$2.14 ▼ $11.88	$117.06M	0.15	92,250 shs	87,157 shs
MYNZ Mainz Biomed	$3.33 -6.5%	$0.92	$0.55 ▼ $4.43	$30.17M	0.31	371,589 shs	8.76 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	0.00%	+15.38%	+20.00%	+89.66%	+229.13%
EQ Equillium	0.00%	+22.83%	+4.63%	+17.71%	+456.65%
KLRS Kalaris Therapeutics	0.00%	+3.80%	-19.48%	-55.15%	+76.34%
MYNZ Mainz Biomed	0.00%	-3.76%	+556.03%	+444.12%	+58.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYPH Cypherpunk Technologies	1.00	Sell	N/A	N/A
EQ Equillium	2.75	Moderate Buy	$7.67	239.23% Upside
KLRS Kalaris Therapeutics	2.75	Moderate Buy	$15.60	217.07% Upside
MYNZ Mainz Biomed	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest MYNZ, EQ, CYPH, and KLRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
5/14/2026	KLRS Kalaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
5/14/2026	KLRS Kalaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
5/13/2026	KLRS Kalaris Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/13/2026	KLRS Kalaris Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$26.00 ➝ $25.00
4/23/2026	EQ Equillium	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/22/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
4/17/2026	EQ Equillium	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
4/16/2026	KLRS Kalaris Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$14.00
4/16/2026	EQ Equillium	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/13/2026	EQ Equillium	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$6.00

(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$0.79 per share	N/A
EQ Equillium	$41.10M	3.48	N/A	N/A	$0.94 per share	2.40
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.88 per share	N/A
MYNZ Mainz Biomed	$659.94K	45.72	N/A	N/A	$2.61 per share	1.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYPH Cypherpunk Technologies	$4.82M	-$0.02	N/A	N/A	N/A	N/A	-48.33%	-42.21%	N/A
EQ Equillium	-$22.40M	-$0.32	N/A	N/A	N/A	N/A	-61.43%	-53.72%	8/13/2026 (Estimated)
KLRS Kalaris Therapeutics	-$43.44M	-$2.15	N/A	N/A	N/A	N/A	-72.78%	-43.49%	N/A
MYNZ Mainz Biomed	-$21.65M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MYNZ, EQ, CYPH, and KLRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/18/2026	Q1 2026	CYPH Cypherpunk Technologies	-$0.0406	-$0.46	-$0.4194	-$0.46	N/A	N/A
5/13/2026	Q1 2026	EQ Equillium	-$0.04	-$0.06	-$0.02	-$0.06	N/A	N/A
5/12/2026	Q1 2026	KLRS Kalaris Therapeutics	-$0.52	-$0.46	+$0.06	-$0.46	N/A	N/A
3/25/2026	Q4 2025	EQ Equillium	-$0.07	-$0.04	+$0.03	-$0.04	N/A	N/A
3/17/2026	Q4 2025	KLRS Kalaris Therapeutics	-$0.56	-$0.44	+$0.12	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYPH Cypherpunk Technologies	N/A	27.28	27.28
EQ Equillium	N/A	18.62	18.62
KLRS Kalaris Therapeutics	N/A	12.19	12.19
MYNZ Mainz Biomed	0.44	0.52	0.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYPH Cypherpunk Technologies	30.46%
EQ Equillium	27.05%
KLRS Kalaris Therapeutics	66.05%
MYNZ Mainz Biomed	N/A

Insider Ownership

Company	Insider Ownership
CYPH Cypherpunk Technologies	3.50%
EQ Equillium	17.84%
KLRS Kalaris Therapeutics	68.10%
MYNZ Mainz Biomed	18.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYPH Cypherpunk Technologies	40	106.46 million	102.74 million	Optionable
EQ Equillium	40	63.23 million	51.95 million	Not Optionable
KLRS Kalaris Therapeutics	110	23.79 million	7.59 million	N/A
MYNZ Mainz Biomed	30	9.06 million	7.41 million	Not Optionable

MYNZ, EQ, CYPH, and KLRS Headlines

Recent News About These Companies

Best Penny Stocks Worth Watching - May 15th

May 17, 2026 | americanbankingnews.com

Mainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)

March 12, 2026 | finanznachrichten.de

Strategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen Chairman

March 11, 2026 | de.investing.com

Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

March 11, 2026 | globenewswire.com

Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples

February 24, 2026 | markets.businessinsider.com

Mainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf Bauchspeicheldrüsenkrebs

February 17, 2026 | de.investing.com

Mainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer program

February 17, 2026 | msn.com

Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update

February 17, 2026 | finance.yahoo.com

Mainz Biomed nimmt 2,15 Mio. US-Dollar über At-the-Market-Platzierung ein/n

February 10, 2026 | de.investing.com

Mainz Biomed Aktie: Neue Studiendaten voraus

February 7, 2026 | stock-world.deS

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

January 14, 2026 | globenewswire.com

Mainz Biomed expects to complete eAArly DETECT 2 study in 2026

January 6, 2026 | msn.com

Mainz Biomed Provides Review of 2025 Highlights

January 5, 2026 | markets.businessinsider.com

Mainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening Program

January 5, 2026 | quiverquant.comQ

2 Small-Cap Biotechs That Could Reward Patient Investors (MYNZ)

...

December 12, 2025 | marketbeat.com

Mainz Biomed files $150M mixed securities shelf

December 5, 2025 | msn.com

Mainz Biomed announces ColoAlert added to portfolio of DoctorBox

December 2, 2025 | msn.com

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio

December 2, 2025 | markets.businessinsider.com

Mainz BioMed NV: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

November 18, 2025 | finanznachrichten.de

Mainz Biomed, OncoVanguard8 agree to bring ColoAlert to South America

November 18, 2025 | msn.com

Mainz Biomed Signs Memorandum of Understanding with OncoVanguard8 to Launch ColoAlert® Colorectal Cancer Screening in South America

November 18, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MYNZ, EQ, CYPH, and KLRS Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

$1.20 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Equillium NASDAQ:EQ

$2.26 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.28 +0.02 (+0.66%)

As of 05/22/2026 07:54 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Kalaris Therapeutics NASDAQ:KLRS

$4.92 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$5.10 +0.18 (+3.56%)

As of 05/22/2026 07:59 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Mainz Biomed NASDAQ:MYNZ

$3.33 -0.23 (-6.46%)

As of 05/22/2026

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MYNZ, EQ, CYPH, and KLRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MYNZ, EQ, CYPH, and KLRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MYNZ, EQ, CYPH, and KLRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MYNZ, EQ, CYPH, and KLRS Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Equillium NASDAQ:EQ

Kalaris Therapeutics NASDAQ:KLRS

Mainz Biomed NASDAQ:MYNZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MYNZ, EQ, CYPH, and KLRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MYNZ, EQ, CYPH, and KLRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MYNZ, EQ, CYPH, and KLRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MYNZ, EQ, CYPH, and KLRS Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Equillium NASDAQ:EQ

Kalaris Therapeutics NASDAQ:KLRS

Mainz Biomed NASDAQ:MYNZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools